ZTS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

2.36B

+1.9%

1.401

+0.11%

2.33B

+4.74%

1.570

+6.11%

2.58B

+4.69%

1.835

+4.26%

Estimates Revision

The market is revising Downward the revenue expectations for Zoetis Inc. (ZTS) for FY2025, with the revenue forecasts being adjusted by -0.82% over the past three months. During the same period, the stock price has changed by -11.60%.

Revenue Estimates for FY2025

Revise Downward

-0.82%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.29%

In Past 3 Month

Stock Price

Go Down

-11.60%

In Past 3 Month

11 Analyst Rating

Wall Street analysts forecast ZTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZTS is 167.25 USD with a low forecast of 130.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

4 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

130.00

Averages

167.25

High

200.00

Current: 0.000

Low

130.00

Averages

167.25

High

200.00

Morgan Stanley

Overweight

downgrade

$175 -> $160

2025-12-18

Reason

Morgan Stanley

Price Target

$175 -> $160

2025-12-18

downgrade

Overweight

Reason

Morgan Stanley lowered the firm's price target on Zoetis to $160 from $175 and keeps an Overweight rating on the shares. For healthcare technology and providers, the firm sees an "attractive backdrop for alpha-generation opportunities" in 2026, the analyst tells investors. Meanwhile, managed care stocks have underperformed in 2025 and are facing "another year of unprecedented policy, reimbursement, and utilization headwinds," the analyst added in a year-ahead outlook note for the Healthcare Services group.

BofA

Buy -> Neutral

downgrade

$165 -> $135

2025-12-15

Reason

BofA

Price Target

$165 -> $135

2025-12-15

downgrade

Buy -> Neutral

Reason

BofA downgraded Zoetis to Neutral from Buy with a price target of $135, down from $165.

HSBC

Buy

downgrade

$180 -> $140

2025-12-10

Reason

HSBC

Price Target

$180 -> $140

2025-12-10

downgrade

Buy

Reason

HSBC lowered the firm's price target on Zoetis to $140 from $180 and keeps a Buy rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, "even more so if AI panic kicks in." HSBC's preferred stocks are "growth bucket ideas," but says "fallen angels and value could work as well."

Barclays

Equal Weight

initiated

$136

2025-12-08

Reason

Barclays

Price Target

$136

2025-12-08

initiated

Equal Weight

Reason

Barclays initiated coverage of Zoetis with an Equal Weight rating and $136 price target. The firm rolled out coverage on the specialty pharmaceuticals industry with a neutral view, saying investor sentiment is improving as companies shift focus to innovation, margin expansion and de-leveraging. The group's pricing headwinds are easing while debt leverage is coming down, the analyst tells investors in a research note. Barclays sees "plenty of opportunity" as the sector "remains in a transition phase."

KeyBanc

initiated

2025-11-20

Reason

KeyBanc

Price Target

2025-11-20

initiated

Reason

KeyBanc initiated coverage of Zoetis with a Sector Weight rating.

KeyBanc

Steve Dechert

Sector Weight

initiated

2025-11-20

Reason

KeyBanc

Steve Dechert

Price Target

2025-11-20

initiated

Sector Weight

Reason

KeyBanc analyst Steve Dechert initiated coverage of Zoetis with a Sector Weight rating. The firm is citing continued headwinds from the launch of the company's OA pain mAb products and increased competition in key franchises, the analyst tells investors in a research note. While KeyBanc recognizes Zoetis's history of excellence in developing innovative products, the firm sees shares as being fairly valued while it awaits new innovative product launches.

Valuation Metrics

The current forward P/E ratio for Zoetis Inc (ZTS.N) is 19.13, compared to its 5-year average forward P/E of 31.67. For a more detailed relative valuation and DCF analysis to assess Zoetis Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

31.67

Current PE

19.13

Overvalued PE

37.89

Undervalued PE

25.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

22.05

Current EV/EBITDA

14.16

Overvalued EV/EBITDA

25.75

Undervalued EV/EBITDA

18.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

9.17

Current PS

5.67

Overvalued PS

10.87

Undervalued PS

7.47

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 228.26% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ZTS News & Events

Events Timeline

No data

News

7.0

2025-12-31Fool

Viking Therapeutics Revives VK2735 Clinical Trials, Potential Market Rebound Ahead

9.0

2025-12-31NASDAQ.COM

Viking Therapeutics Advances VK2735 to Phase 3 Trials for Weight Management

5.0

2025-12-30Yahoo Finance

Zoetis Receives Health Canada Approval for Portela, New OA Pain Relief for Cats

People Also Watch

Frequently Asked Questions

What is Zoetis Inc (ZTS) stock price today?

The current price of ZTS is 126.85 USD — it has increased 0.94 % in the last trading day.

What is Zoetis Inc (ZTS)'s business?

Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).

What is the price predicton of ZTS Stock?

What is Zoetis Inc (ZTS)'s revenue for the last quarter?

Zoetis Inc revenue for the last quarter amounts to 2.40B USD, increased 0.50 % YoY.

What is Zoetis Inc (ZTS)'s earnings per share (EPS) for the last quarter?

Zoetis Inc. EPS for the last quarter amounts to 1.63 USD, increased 8.67 % YoY.

What changes have occurred in the market's expectations for Zoetis Inc (ZTS)'s fundamentals?

How many employees does Zoetis Inc (ZTS). have?

Zoetis Inc (ZTS) has 13800 emplpoyees as of January 08 2026.

What is Zoetis Inc (ZTS) market cap?

Today ZTS has the market capitalization of 55.90B USD.